Skip to main content
Top
Published in: Diabetologia 1/2012

01-01-2012 | Short Communication

Audit of acute Charcot’s disease in the UK: the CDUK study

Authors: F. L. Game, R. Catlow, G. R. Jones, M. E. Edmonds, E. B. Jude, G. Rayman, W. J. Jeffcoate

Published in: Diabetologia | Issue 1/2012

Login to get access

Abstract

Aims/hypothesis

We studied factors associated with the development and resolution of acute Charcot foot using a web-based observational study.

Methods

Clinicians managing cases of acute Charcot foot in the UK and Ireland between June 2005 and February 2007 were invited to register anonymised details on a secure website.

Results

A total of 288 cases (age 57.0 ± 11.3 years [mean ± SD]; 71.2% male) were registered from 76 centres. Of these, 36% of patients recalled an episode of relevant trauma in the preceding 6 months, while 12% had had surgery to the affected foot. In 101 (35%) cases, ulceration was present at registration and 20% of these had osteomyelitis. Non-removable off-loading devices were used at presentation in 35.4% of cases, with removable off-loading used in 50%. Data on resolution were available for 219 patients. The median time to resolution was 9 months in patients whose initial management included the use of non-removable off-loading, compared with 12 months in the remainder (p = 0.001). Bisphosphonates were administered intravenously in 25.4% and orally in 19.4% of cases. The median time to resolution in patients who received bisphosphonates was 12 months and was longer than in those who did not (10 months, p = 0.005).

Conclusions/interpretation

The median time to resolution was longer than in earlier series. Although limited by being observational and non-randomised, these data suggest that the use of non-removable off-loading at presentation may shorten the time to resolution. They provide no evidence to indicate that the use of bisphosphonates is beneficial.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085–1096PubMedCrossRef Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085–1096PubMedCrossRef
3.
go back to reference Frykberg RG, Kozak GP (1978) Neuropathic arthropathy in the diabetic foot. Am Fam Physician 17:105–113PubMed Frykberg RG, Kozak GP (1978) Neuropathic arthropathy in the diabetic foot. Am Fam Physician 17:105–113PubMed
4.
go back to reference Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058–2061PubMedCrossRef Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058–2061PubMedCrossRef
5.
go back to reference Jeffcoate WJ, Game FL (2010) New theories on the cause of the Charcot foot of diabetes. In: Frykberg R (ed) The Charcot foot and ankle DTP. Towson, Maryland, pp 29–43 Jeffcoate WJ, Game FL (2010) New theories on the cause of the Charcot foot of diabetes. In: Frykberg R (ed) The Charcot foot and ankle DTP. Towson, Maryland, pp 29–43
6.
go back to reference Uccioli L, Sinistro A, Almerighi C et al (2010) Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 33:350–355PubMedCrossRef Uccioli L, Sinistro A, Almerighi C et al (2010) Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 33:350–355PubMedCrossRef
7.
go back to reference Pitocco D, Zetano G, Gioffre G et al (2009) Association between osteoprotegerin G1181 and T245G polymorphisms and diabetic Charcot neuroarthropathy. Diabetes Care 32:1694–1697PubMedCrossRef Pitocco D, Zetano G, Gioffre G et al (2009) Association between osteoprotegerin G1181 and T245G polymorphisms and diabetic Charcot neuroarthropathy. Diabetes Care 32:1694–1697PubMedCrossRef
8.
go back to reference Sinacore DR (1996) Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location. J Diabetes Complications 12:287–293CrossRef Sinacore DR (1996) Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location. J Diabetes Complications 12:287–293CrossRef
9.
go back to reference Pinzur MS, Lio T, Posner M (2006) Treatment of Eichenholtz stage I Charcot foot arthropathy with a weightbearing total contact cast. Foot Ankle Int 27:324–329PubMed Pinzur MS, Lio T, Posner M (2006) Treatment of Eichenholtz stage I Charcot foot arthropathy with a weightbearing total contact cast. Foot Ankle Int 27:324–329PubMed
10.
go back to reference Pakarinen TK, Laine HJ, Honkonen SE, Peltonen J, Oksala H, Lahtela J (2002) Charcot arthropathy of the diabetic foot. Current concepts and review of 36 cases. Scand J Surg 91:195–201PubMed Pakarinen TK, Laine HJ, Honkonen SE, Peltonen J, Oksala H, Lahtela J (2002) Charcot arthropathy of the diabetic foot. Current concepts and review of 36 cases. Scand J Surg 91:195–201PubMed
11.
go back to reference Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR (1997) The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 14:357–363PubMedCrossRef Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR (1997) The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 14:357–363PubMedCrossRef
12.
go back to reference Selby PL, Young MJ, Boulton AJM (1993) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy. Diabet Med 11:28–31CrossRef Selby PL, Young MJ, Boulton AJM (1993) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy. Diabet Med 11:28–31CrossRef
13.
go back to reference Jude EB, Selby PL, Burgess J et al (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double blind randomised controlled trial. Diabetologia 44:2032–2037PubMedCrossRef Jude EB, Selby PL, Burgess J et al (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double blind randomised controlled trial. Diabetologia 44:2032–2037PubMedCrossRef
14.
go back to reference Pitocco D, Rutolo R, Caputo S et al (2005) Six month treatment with alendronate in acute Charcot neuropathy. Diabetes Care 28:1214–1215PubMedCrossRef Pitocco D, Rutolo R, Caputo S et al (2005) Six month treatment with alendronate in acute Charcot neuropathy. Diabetes Care 28:1214–1215PubMedCrossRef
15.
go back to reference Pakarinen TK, Laine HJ, Mäenpää H, Mattrila P, Lahtela J (2011) The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes Care 34:1514–1516PubMedCrossRef Pakarinen TK, Laine HJ, Mäenpää H, Mattrila P, Lahtela J (2011) The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes Care 34:1514–1516PubMedCrossRef
Metadata
Title
Audit of acute Charcot’s disease in the UK: the CDUK study
Authors
F. L. Game
R. Catlow
G. R. Jones
M. E. Edmonds
E. B. Jude
G. Rayman
W. J. Jeffcoate
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2354-7

Other articles of this Issue 1/2012

Diabetologia 1/2012 Go to the issue